News
RGNX
16.06
+0.12%
0.02
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
The REGENXBIO Inc. Share price has softened a substantial 26% over the last 30 days. The company's price-to-sales ratio of 8.7x is lower than the Biotechs industry average. Its declining revenue compares poorly to other companies in the same industry. The stock is expected to perform worse than its peers in the coming years.
Simply Wall St · 1d ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 2d ago
Weekly Report: what happened at RGNX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at RGNX last week (0408-0412)?
Weekly Report · 04/15 09:25
Institutional owners may consider drastic measures as REGENXBIO Inc.'s (NASDAQ:RGNX) recent US$53m drop adds to long-term losses
Institutional investors own over 50% of REGENXBIO Inc. (NASDAQ:RGNX) The top 6 shareholders of the company own 53% of the stock. In the last year, the company has lost 4.6% of its market value. With a 72% stake, institutions have significant influence over the company's share price. RegenxBIO has a high level of insider ownership, but the company is not in sync with other shareholders. We look at the ownership structure of RegenXBIo Inc. To see how the company operates.
Simply Wall St · 04/14 12:48
REGENXBIO Is Maintained at Buy by Stifel
Dow Jones · 04/12 16:03
Where Regenxbio Stands With Analysts
Regenxbio is a biotechnology company developing a gene therapy. The company has an average price target of $38.22. The 12-month price target is up 1.25% from the previous average of $37.75. Regenxbio has 9 analysts' ratings ranging from bullish to bearish.
Benzinga · 04/12 16:01
Commit To Purchase REGENXBIO At $7.50, Earn 10.1% Annualized Using Options
NASDAQ · 04/09 15:33
Weekly Report: what happened at RGNX last week (0401-0405)?
Weekly Report · 04/08 09:26
Weekly Report: what happened at RGNX last week (0325-0329)?
Weekly Report · 04/01 09:26
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
Results from the Phase I/IIa trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration are published in The Lancet. The positive study results informed the ongoing pivotal trials of a potential gene therapy for wet AMD.
Benzinga · 03/28 11:09
12 Health Care Stocks Moving In Monday's After-Market Session
Stoke Therapeutics (NASDAQ:STOK) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. OpGen shares moved upwards by 66.61% as the Q4 earnings report came out today.
Benzinga · 03/25 21:32
Weekly Report: what happened at RGNX last week (0318-0322)?
Weekly Report · 03/25 09:27
Weekly Report: what happened at RGNX last week (0311-0315)?
Weekly Report · 03/18 09:26
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
New clinical data from Regenxbio shows a gene therapy for Duchenne muscular dystrophy is making headway. Sarepta Therapeutics could have a serious new competitor on the horizon. The company is developing a drug to treat the disease. But the company may not be a serious threat to Sarepta's business.
The Motley Fool · 03/13 12:00
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)
TipRanks · 03/12 02:10
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
RegenXBIO Inc. (NASDAQ:RGNX) has made remarkable progress in advancing its pipeline of gene therapies. The company has reported positive interim results from a study using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. It is also on track to file a BLA for its MPS II program in 2024. The odds of the company reaching the finish line have been upgraded from buy to strong buy. Its NAV Technology Platform is building upon next-generation AAV vectors to enhance efficacy.
Seeking Alpha · 03/11 15:53
REGENXBIO Price Target Announced at $36.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 13:47
REGENXBIO Initiated at Buy by HC Wainwright & Co.
Dow Jones · 03/11 13:47
Regenxbio: Current report
Press release · 03/11 12:06
More
Webull provides a variety of real-time RGNX stock news. You can receive the latest news about Regenxbio through multiple platforms. This information may help you make smarter investment decisions.
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.